ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), an ophthalmic pharmaceutical company, announced results from the Company's recently completed Phase III clinical program of Xibrom(TM) (0.09% bromfenac sodium ophthalmic solution) QD (once-daily). The program enrolled 282 patients who underwent cataract surgery in two U.S.
[Sadece Üyeler Görebilir. Üye olmak için tiklayiniz...]
ISTA Pharmaceuticals Announces Phase III Results For Once-Daily Topical Xibrom(TM) 0.09%
Normal Mod
